Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series

Theerada Assawasaksakul; Seelwan Sathitratanacheewin; Preeyaporn Vichaiwattana; Nasamon Wanlapakorn; Yong Poovorawan; Wonngarm Kittanamongkolchai

doi:10.1136/rmdopen-2021-002019

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest Content

Archive

For authors

About

Podcasts
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

PDF

Lupus

Clinical case

Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Assawasaksakul T, Sathitratanacheewin S, Vichaiwattana P, et al

Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series

RMD Open 2021;7:e002019. doi: 10.1136/rmdopen-2021-002019

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password